TLDR JAK inhibitors show promise as a future treatment for hair loss.
The document discussed the potential of Janus kinase (JAK) inhibitors as a promising future treatment for alopecia areata. It highlighted the therapeutic potential of JAK inhibitors in addressing this autoimmune condition, which causes hair loss. The letter emphasized the need for further research to fully understand the efficacy and safety of these inhibitors in treating alopecia areata.
77 citations,
June 2017 in “Advances in Therapy” New treatments for Alopecia Areata, like JAK inhibitors, show promise for hair regrowth and are likely to change future treatment approaches.
355 citations,
January 2017 in “Journal of the American Academy of Dermatology” JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.
16 citations,
January 2017 in “Acta dermatovenerologica Alpina, Pannonica et Adriatica (Tiskana izd.)” A patient with complete hair loss regrew all her hair using tofacitinib.
238 citations,
November 2016 in “Journal of The American Academy of Dermatology” Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
April 2019 in “International journal of research in dermatology” A child with rough nails also had hair loss and allergies.
